



HU000026278T2

(19) **HU****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 026 278**(13) **T2****EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA(21) Magyar ügyszám: **E 04 743158**(22) A bejelentés napja: **2004. 07. 01.**(51) Int. Cl.: **A61K 39/00** (2006.01)**C07K 16/00** (2006.01)

(96) Az európai bejelentés bejelentési száma:

EP 20040743158

(86) A nemzetközi (PCT) bejelentési szám:

PCT/GB 04/002810

(97) Az európai bejelentés közzétételi adatai:

EP 1644412 A2 **2005. 01. 13.**

(87) A nemzetközi közzétételi szám:

WO 05003169

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 1644412 B1 **2015. 09. 09.**

(30) Elsőbbségi adatok:

0315457 **2003. 07. 01.** **GB****0319588** **2003. 08. 20.** **GB**

(73) Jogosult(ak):

UCB Biopharma SPRL, 1070 Brussels (BE)

(72) Feltaláló(k):

HUMPHREYS, David Paul, Slough, Berkshire SL1 3WE
(GB)**HEYWOOD, Sam Philip, Slough, Berkshire SL1 3WE**
(GB)

(74) Képviselő:

dr. Pethő Árpád, DANUBIA Szabadalmi és
Jogi Iroda Kft., Budapest

(54)

Módosított Fab-ellenanyagfragmensek

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.

(19)



(11)

EP 1 644 412 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
09.09.2015 Bulletin 2015/37

(21) Application number: **04743158.0**

(22) Date of filing: **01.07.2004**

(51) Int Cl.:
A61K 39/00 ^(2006.01) **C07K 16/00** ^(2006.01)

(86) International application number:
PCT/GB2004/002810

(87) International publication number:
WO 2005/003169 (13.01.2005 Gazette 2005/02)

(54) **MODIFIED ANTIBODY FAB FRAGMENTS**

MODIFIZIERTE FAB-ANTIKÖRPER-FRAGMENTE

FRAGMENTS D'ANTICORPS FAB MODIFIES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL HR LT LV MK

(30) Priority: **01.07.2003 GB 0315457**
20.08.2003 GB 0319588

(43) Date of publication of application:
12.04.2006 Bulletin 2006/15

(73) Proprietor: **UCB Biopharma SPRL**
1070 Brussels (BE)

(72) Inventors:
• **HUMPHREYS, David Paul**
Slough, Berkshire SL1 3WE (GB)
• **HEYWOOD, Sam Philip**
Slough, Berkshire SL1 3WE (GB)

(74) Representative: **Thompson, John**
UCB Celltech,
208 Bath Road
Slough, Berkshire SL1 3WE (GB)

(56) References cited:
WO-A-98/25971

- **TOUT N L ET AL:** "Phage display and bacterial expression of a recombinant Fab specific for *Pseudomonas aeruginosa* serotype O6 lipopolysaccharide" **CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 4, no. 2, March 1997 (1997-03), pages 147-155, XP002258884 ISSN: 1071-412X**
- **KHAWLI LESLIE A ET AL:** "Stable, genetically engineered F(ab')₂ fragments of chimeric TNT-3 expressed in mammalian cells" **HYBRIDOMA AND HYBRIDOMICS, vol. 21, no. 1, February 2002 (2002-02), pages 11-18, XP002314088 ISSN: 1536-8599**
- **CHAPMAN A P ET AL:** "THERAPEUTIC ANTIBODY FRAGMENTS WITH PROLONGED IN VIVO HALF-LIVES" **NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 17, no. 8, August 1999 (1999-08), pages 780-783, XP001199462 ISSN: 1087-0156**
- **LEONG STEVEN R ET AL:** "Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation" **CYTOKINE, vol. 16, no. 3, 7 November 2001 (2001-11-07), pages 106-119, XP002314089 ISSN: 1043-4666**
- **CHAPMAN ANDREW P:** "PEGylated antibodies and antibody fragments for improved therapy: A review", **ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 531-545, XP002300924, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(02)00026-1**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 644 412 B1

- | | |
|---|---|
| <ul style="list-style-type: none">• CHAPMAN A P: "PEGYLATED ANTIBODIES AND ANTIBODY FRAGMENTS FOR IMPROVED THERAPY: A REVIEW", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 531-545, XP001199533, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(02)00026-1 | <ul style="list-style-type: none">• SINGH RAJEEVA ET AL: "Labeling of antibodies by in situ modification of thiol groups generated from selenol-catalyzed reduction of native disulfide bonds", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC, NEW YORK, vol. 304, no. 2, 1 January 2002 (2002-01-01), pages 147-156, XP001165655, ISSN: 0003-2697, DOI: 10.1006/ABIO.2002.5624 |
|---|---|

Description

[0001] The present invention relates to improved antibody fragments and more specifically provides improved antibody fragments to which one or more, preferably two or more, effector molecules are attached and methods for their production.

[0002] The high specificity and affinity of antibody variable regions make them ideal diagnostic and therapeutic agents, particularly for modulating protein:protein interactions. Antibody fragments are proving to be versatile therapeutic agents, as seen by the recent success of products such as ReoPro®. A bacterial expression of a recombinant Fab fragment was disclosed in Tout N L et al., 1997, Clinical and Diagnostic Laboratory Immunology, vol. 4, no. 2, 147-155. Therapeutic antibody fragments with prolonged in vivo half-lives were disclosed in Chapman A P et al., 1999, Nature Biotechnology, vol. 17, no. 8, 780-783. The targeting function encoded in Fv, Fab, Fab', F(ab)₂ and other antibody fragments can be used directly or can be conjugated to one or more effector molecules such as cytotoxic drugs, toxins or polymer molecules to increase efficacy. For example, since these fragments lack an Fc region they have a short circulating half-life in animals but this can be improved by conjugation to certain types of polymer such as polyethylene glycol (PEG). Increasing the size of the conjugated PEG has been shown to increase the circulating half-life from minutes to many hours and modification of a Fab' with PEG ranging from 5kDa to 100kDa has been demonstrated (Chapman et al., 1999, Nature Biotechnology, 17, 780-783; Leong et al., 2001, Cytokine, 16, 106-119; Chapman, 2002, Advanced Drug Delivery Reviews, 54, 531-545). PEGylated antibody fragments such as CDP870 are currently undergoing clinical trials where the effect of the conjugated PEG is to bring the circulating half-life to acceptable levels for therapy.

[0003] Effector molecules may be attached to antibody fragments by a number of different methods, including through aldehyde sugars or more commonly through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. The site of attachment of effector molecules can be either random or site specific.

[0004] Random attachment is often achieved through amino acids such as lysine and this results in effector molecules being attached at a number of sites throughout the antibody fragment depending on the position of the lysines. While this has been successful in some cases the exact location and number of effector molecules attached cannot be controlled and this can lead to loss of activity for example if too few are attached and/or loss of affinity if for example they interfere with the binding site (Chapman 2002 Advanced Drug Delivery Reviews, 54, 531-545). As a result, controlled site specific attachment of effector molecules is usually the method of choice.

[0005] Site specific attachment of effector molecules is most commonly achieved by attachment to cysteine residues since such residues are relatively uncommon in antibody fragments. Antibody hinges are popular regions for site specific attachment since these contain cysteine residues and are remote from other regions of the antibody likely to be involved in antigen binding. Suitable hinges either occur naturally in the fragment or may be created using recombinant DNA techniques (See for example US 5,677,425; WO98/25971; Leong et al., 2001 Cytokine, 16, 106-119; Chapman et al., 1999 Nature Biotechnology, 17, 780-783). Alternatively, or in addition, site specific cysteines may be engineered into the antibody fragment for example to create surface exposed cysteine(s) (US 5,219,996).

[0006] Where effector molecules are to be site specifically attached via a cysteine, the target thiol in the antibody fragment is often capped by a small fermentation related peptide product such as glutathione or deliberately capped by a chemical additive used during antibody fragment extraction and purification such as 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB). These capping agents need to be removed to activate the target (hinge or surface) thiol. Antibody fragments have a native interchain disulphide bond between the heavy and light chain constant regions (C_H1 and C_L) that has generally been regarded as critical in maintaining the stability and binding properties of the antibody. As a result the activation of the target hinge or surface thiol must be carried out with some care such that the inter C_L:C_H1 disulphide remains intact. Hence 'mild' reducing conditions are conventionally used to remove the thiol capping agent prior to reaction with the effector molecule. This is usually achieved by using thiol based reductants such as β-mercaptoethanol (β-ME), (β-mercaptoethylamine (β-MA) and dithiothreitol (DTT). However, each of these reductants is known to be able to react with and stay attached to the cysteine which it is meant to reduce (Begg and Speicher, 1999 Journal of Biomolecular techniques, 10, 17-20) thereby reducing the efficiency of effector molecule attachment. Hence, following reduction and reaction with effector molecules, a large proportion of the antibody fragments do not have any effector molecules attached and these have to be purified away from the antibody fragments that have the correct number of effector molecules attached. This poor efficiency of modification is clearly a disadvantage during the large-scale production of modified therapeutic antibody fragments where it is important that maximum production efficiency is achieved.

[0007] The present invention provides a new class of antibody Fab fragments to which effector molecules may be attached. A particular advantage of these fragments lies in the cysteine residues present in these fragments that may be used for site specific effector molecule attachment avoiding the need to engineer modified hinge regions and/or surface amino acid substitutions. When effector molecules are attached to the antibody Fab fragments of the present invention there are no inter-chain covalent linkages between the heavy and light chain. Despite the absence of any covalent linkage between the heavy and the light chain and the attachment of effector molecules, the fragments of the present invention perform comparably with wild type fragments in a number of *in vitro* and *in vivo* tests. Surprisingly

these novel fragments have the same affinity for antigen and similar *in vivo* and *in vitro* stability as wild type fragments. A further advantage of these fragments lies in the ease of attachment of effector molecules to the fragments, and in particular, the efficiency of attachment. The fragments thus provide a low cost alternative to currently available fragments in which the native inter-chain covalent linkages are retained following effector molecule attachment.

[0008] Thus according to the present invention there is provided an antibody Fab fragment characterized in that the heavy chain constant region terminates at the interchain cysteine of C_H1.

[0009] The antibody Fab fragment of the present invention may be any heavy chain and light chain pair having a variable (V_H/V_L) and constant region (C_H/C_L). Preferably the heavy and light chain pair is V_H/C_H1 and V_L/C_L covalently linked through interchain cysteines in the heavy and light chain constant regions. The term 'interchain cysteine' as used herein refers to a cysteine in the heavy or light chain constant region that would be disulphide linked to a cysteine in the corresponding heavy or light chain constant region encoded in a naturally occurring germline antibody gene. In particular the interchain cysteines of the present invention are a cysteine in the constant region of the light chain (C_L) and a cysteine in the first constant region of the heavy chain (C_H1) that are disulphide linked to each other in naturally occurring antibodies. Examples of such cysteines may typically be found at position 214 of the light chain and 233 of the heavy chain of human IgG1, 127 of the heavy chain of human IgM, IgE, IgG2, IgG3, IgG4 and 128 of the heavy chain of human IgD and IgA2B, as defined by Kabat et al., 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA. In murine IgG, interchain cysteines may be found at position 214 of the light chain and 235 of the heavy chain. It will be appreciated that the exact positions of these cysteines may vary from that of naturally occurring antibodies if any modifications, such as deletions, insertions and/or substitutions have been made to the antibody Fab fragment.

[0010] In the antibody Fab fragment of the present invention the heavy chain constant region terminates at the interchain cysteine of C_H1. Hence the last amino acid in the C_H1 domain of the antibody Fab fragment of the present invention is a cysteine. The antibody Fab fragment of the present invention in which the C_H1 domain is truncated may be prepared by any suitable method known in the art. For example, the antibody Fab fragment of the present invention may be obtained from any whole antibody, especially a whole monoclonal antibody, using any suitable enzymatic cleavage and/or digestion techniques, for example by treatment with pepsin or papain and c-terminal proteases. Preferably the antibody Fab fragment of the present invention is prepared by the use of recombinant DNA techniques involving the manipulation and re-expression of DNA encoding antibody variable and constant regions. Standard molecular biology techniques may be used to modify, add or delete further amino acids or domains as desired. Any alterations to the variable or constant regions are still encompassed by the terms 'variable' and 'constant' regions as used herein. Preferably PCR is used to introduce a stop codon immediately following the codon encoding the interchain cysteine of C_H1, such that translation of the C_H1 domain stops at the interchain cysteine. Methods for designing suitable PCR primers are well known in the art and the sequences of antibody C_H1 domains are readily available (Kabat *et al.*, *supra*). Alternatively stop codons may be introduced using site-directed mutagenesis techniques such as those described in White (Ed.), PCR Protocols: Current Methods and Applications (1993). The antibody fragment starting material of the present invention may be derived from any antibody isotype including for example IgG, IgM, IgA, IgD and IgE and subclasses thereof including for example IgG1, IgG2, IgG3 and IgG4. Preferably the antibody Fab fragment of the present invention is derived from IgG1. The antibody fragment starting material may be obtained from any species including for example mouse, rat, rabbit, pig, hamster, camel, llama, goat or human. Parts of the antibody fragment may be obtained from more than one species for example the antibody fragments may be chimeric. In one example the constant regions are from one species and the variable regions from another. The antibody fragment starting material may also be modified. In one example the variable region of the antibody fragment has been created using recombinant DNA engineering techniques. Such engineered versions include those created for example from natural antibody variable regions by insertions, deletions or changes in or to the amino acid sequences of the natural antibodies. Particular examples of this type include those engineered variable region domains containing at least one CDR and optionally one or more framework amino acids from one antibody and the remainder of the variable region domain from a second antibody. The methods for creating and manufacturing these antibody fragments are well known in the art (see for example, Boss et al., US 4,816,397; Cabilly et al., US 6,331,415; Shrader et al., WO 92/02551; Orlandi et al., 1989, Proc.Natl.Acad.Sci. USA, 86, 3833; Riechmann et al., 1988, Nature, 322, 323; Queen et al., US 5,585,089; Adair, WO91/09967; Mountain and Adair, 1992, Biotechnol. Genet. Eng. Rev, 10, 1-142; Verma et al., 1998, Journal of Immunological Methods, 216, 165-181).

[0011] The antibody fragment of the present invention will in general be capable of selectively binding to an antigen. The antigen may be any cell-associated antigen, for example a cell surface antigen on cells such as bacterial cells, yeast cells, T-cells, endothelial cells or tumour cells, or it may be a soluble antigen. Antigens may also be any medically relevant antigen such as those antigens upregulated during disease or infection, for example receptors and/or their corresponding ligands. Particular examples of cell surface antigens include adhesion molecules, for example integrins such as β 1 integrins e.g. VLA-4, E-selectin, P selectin or L-selectin, CD2, CD3, CD4, CD5, CD7, CD8, C11a, CD11b, CD18, CD19, CD20, CD23, CD25, CD33, CD38, CD40, CD45, CDW52, CD69, carcinoembryonic antigen (CEA), human milk fat globulin (HMFG1 and 2), MHC Class I and MHC Class II antigens, and VEGF, and where appropriate, receptors thereof.

Soluble antigens include interleukins such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, IL-16 or IL-17, viral antigens for example respiratory syncytial virus or cytomegalovirus antigens, immunoglobulins, such as IgE, interferons such as interferon α , interferon β or interferon γ , tumour necrosis factor- α , tumor necrosis factor- β , colony stimulating factors such as G-CSF or GM-CSF, and platelet derived growth factors such as PDGF- α , and PDGF- β and where appropriate receptors thereof.

[0012] The present invention provides an antibody Fab fragment characterized in that the heavy chain constant region terminates at the interchain cysteine of C_H1. In one embodiment the heavy chain and light chain constant regions are derived from human IgG1. In one embodiment the present invention provides an antibody Fab fragment in which the heavy chain constant region comprises or consists of the amino acid sequence provided in SEQ ID NO: 1. The present invention also provides an antibody Fab fragment in which the heavy chain constant region comprises or consists of the amino acid sequence provided in SEQ ID NO:1 and the light chain constant region comprises or consists of the amino acid sequence provided in SEQ ID NO:2. All sequences and their SEQ ID numbers are provided in Figure 5.

[0013] In another embodiment the heavy and light chain constant regions are derived from murine IgG1. In this aspect the present invention provides an antibody Fab fragment in which the heavy chain constant region comprises or consists of the amino acid sequence provided in SEQ ID NO: 3. The present invention also provides an antibody Fab fragment in which the heavy chain constant region comprises or consists of the amino acid sequence provided in SEQ ID NO:3 and the light chain constant region comprises or consists of the amino acid sequence provided in SEQ ID NO:4.

[0014] The present invention also provides an antibody Fab fragment wherein the constant region of the heavy chain comprises or consists of a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO:1.

[0015] "Identity", as used herein, indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. "Similarity", as used herein, indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. For example, leucine may be substituted for isoleucine or valine. Other amino acids which can often be substituted for one another include but are not limited to:

- phenylalanine, tyrosine and tryptophan (amino acids having aromatic side chains);
- lysine, arginine and histidine (amino acids having basic side chains);
- aspartate and glutamate (amino acids having acidic side chains);
- asparagine and glutamine (amino acids having amide side chains); and
- cysteine and methionine (amino acids having sulphur-containing side chains).

Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). Preferably, the antibody Fab fragment of this aspect of the present invention comprises a heavy chain, wherein the constant region of the heavy chain comprises a sequence having at least 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:1.

[0016] The present invention also provides an antibody Fab fragment wherein the constant region of the heavy chain comprises or consists of a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO:1 and the constant region of the light chain comprises or consists of a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO:2. Preferably, the antibody Fab fragment of this aspect of the present invention comprises a heavy chain, wherein the constant region of the heavy chain comprises a sequence having at least 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:1 and a light chain wherein the constant region of the light chain comprises a sequence having at least 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:2.

[0017] The present invention also provides an antibody Fab fragment wherein the constant region of the heavy chain comprises or consists of a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO:3. In one embodiment, the present invention provides an antibody Fab fragment wherein the constant region of the heavy chain comprises or consists of a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO:3 and the constant region of the light chain comprises or consists of a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO:4. Preferably, the antibody Fab fragment of this aspect of the present invention comprises a heavy chain, wherein the constant region of the heavy chain comprises a sequence having at least 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:3 and a light chain wherein the constant region of the light chain comprises a sequence having at least 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:4.

[0018] Nucleic acid sequences which encode the the amino acid sequences provided in SEQ ID NOs 1-4 can be designed using known methods in the art. In one embodiment the invention provides isolated DNA sequences encoding

the heavy and/or light chain constant regions provided in SEQ ID NOs 1-4. In one embodiment the nucleic acid sequences encoding the amino acid sequences provided in SEQ ID NOs 1, 2, 3 and 4 are those given in SEQ ID NOs 5, 6, 7 and 8 respectively.

[0019] The present invention also relates to a cloning or expression vector comprising one or more DNA sequences of the present invention. Accordingly, provided is a cloning or expression vector comprising one or more DNA sequences encoding an antibody Fab fragment of the present invention. In particular cloning or expression vectors of the present invention comprise one or more DNA sequences encoding the antibody constant regions of the present invention, as provided in SEQ ID NOs 5-8. In one embodiment the vector comprises the sequence given in SEQ ID NO:5 and SEQ ID NO:6. In another embodiment the vector comprises the sequence given in SEQ ID NO:7 and SEQ ID NO:8.

[0020] General methods by which the vectors may be constructed, transfection methods and culture methods are well known to those skilled in the art. In this respect, reference is made to "Current Protocols in Molecular Biology", 1999, F. M. Ausubel (ed), Wiley Interscience, New York and the Maniatis Manual produced by Cold Spring Harbor Publishing.

[0021] Also provided by the present invention is a host cell expressing an antibody Fab fragment in which the C_H1 domain terminates at the interchain cysteine. Any suitable host cell/vector system may be used for the expression of the DNA sequences encoding the antibody Fab of the present invention. Also provided therefore is a host cell comprising one or more cloning or expression vectors comprising one or more DNA sequences encoding an antibody fragment of the present invention. In particular host cells comprising cloning or expression vectors of the present invention comprising one or more DNA sequences encoding the antibody constant regions of the present invention, as provided in SEQ ID NOs 5-8. Bacterial, for example *E. coli*, and other microbial systems may be used or eukaryotic, for example mammalian host cell expression systems may also be used. Suitable *E. coli* strains for use in the present invention may be naturally occurring strains or mutated strains capable of producing recombinant proteins. Examples of specific host *E. coli* strains include MC4100, TG1, TG2, DHB4, DH5 α , DH1, BL21, XL1Blue and W3110 (ATCC 27,325). Suitable mammalian host cells include CHO, myeloma or hybridoma cells. Also provided is a method of producing the antibody Fab fragment of the present invention comprising culturing the host cell expressing the antibody Fab fragment of the present invention and isolating said fragment. Once produced in the host cell the antibody Fab fragment may be extracted and purified using any suitable method known in the art. Heat extraction may be used as described in US 5,665,866 due to the presence of the interchain disulphide bond. Suitable purification methods include but are not limited to size exclusion, hydrophobic interaction chromatography, protein A, G or L affinity chromatography and ion exchange.

[0022] If desired, the antibody Fab fragment of the present invention may have one or more effector molecules attached to it. The term effector molecule as used herein includes, for example, antineoplastic agents, drugs, toxins (such as enzymatically active toxins of bacterial or plant origin and fragments thereof e.g. ricin and fragments thereof) biologically active proteins, for example enzymes, other antibody or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof e.g. DNA, RNA and fragments thereof, radionuclides, particularly radioiodide, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.

[0023] Particular antineoplastic agents include cytotoxic and cytostatic agents for example alkylating agents, such as nitrogen mustards (e.g. chlorambucil, melphalan, mechlorethamine, cyclophosphamide, or uracil mustard) and derivatives thereof, triethylenephosphoramide, triethylenethiophosphoramide, busulphan, or cisplatin; antimetabolites, such as methotrexate, fluorouracil, floxuridine, cytarabine, mercaptopurine, thioguanine, fluoroacetic acid, or fluorocitric acid, antibiotics, such as bleomycins (e.g. bleomycin sulphate), doxorubicin, daunorubicin, mitomycins (e.g. mitomycin C), actinomycins (e.g. dactinomycin) plicamycin, calicheamicin and derivatives thereof, or esperamicin and derivatives thereof; mitotic inhibitors, such as etoposide, vincristine or vinblastine and derivatives thereof; alkaloids such as ellipticine; polyols such as taxicin-I or taxicin-II; hormones, such as androgens (e.g. dromostanolone or testolactone), progestins (e.g. megestrol acetate or medroxyprogesterone acetate), estrogens (e.g. dimethylstilbestrol diphosphate, polyestradiol phosphate or estramustine phosphate) or antiestrogens (e.g. tamoxifen); anthraquinones, such as mitoxantrone, ureas, such as hydroxyurea; hydrazines, such as procarbazine; or imidazoles, such as dacarbazine.

[0024] Chelated metals include chelates of di- or tripositive metals having a coordination number from 2 to 8 inclusive. Particular examples of such metals include technetium (Tc), rhenium (Re), cobalt (Co), copper (Cu), gold (Au), silver (Ag), lead (Pb), bismuth (Bi), indium (In), gallium (Ga), yttrium (Y), terbium (Tb), gadolinium (Gd), and scandium (Sc). In general the metal is preferably a radionuclide. Particular radionuclides include ^{99m}Tc, ¹⁸⁶Re, ¹⁸⁸Re, ⁵⁸Co, ⁶⁰Co, ⁶⁷Cu, ¹⁹⁵Au, ¹⁹⁹Au, ¹¹⁰Ag, ²⁰³Pb, ²⁰⁶Bi, ²⁰⁷Bi, ¹¹¹In, ⁶⁷Ga, ⁶⁸Ga, ⁸⁸Y, ⁹⁰Y, ¹⁶⁰Tb, ¹⁵³Gd and ⁴⁷Sc.

[0025] The chelated metal may be for example one of the above types of metal chelated with any suitable polydentate chelating agent, for example acyclic or cyclic polyamines, polyethers, (e.g. crown ethers and derivatives thereof); polyamides; porphyrins; and carbocyclic derivatives.

[0026] In general, the type of chelating agent will depend on the metal in use. One particularly useful group of chelating agents in conjugates according to the invention, however, are acyclic and cyclic polyamines, especially polyaminocarboxylic acids, for example diethylenetriaminepentaacetic acid and derivatives thereof, and macrocyclic amines, e.g. cyclic tri-aza and tetra-aza derivatives (for example as described in International Patent Specification No. WO 92/22583);

and polyamides, especially desferriox-amine and derivatives thereof.

[0027] Other effector molecules include proteins, peptides and enzymes. Enzymes of interest include, but are not limited to, proteolytic enzymes, hydrolases, lyases, isomerases, transferases. Proteins, polypeptides and peptides of interest include, but are not limited to, immunoglobulins, toxins such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin, a protein such as insulin, tumour necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor or tissue plasminogen activator, a thrombotic agent or an anti-angiogenic agent, e.g. angiostatin or endostatin, or, a biological response modifier such as a lymphokine, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), nerve growth factor (NGF) or other growth factor and immunoglobulins.

[0028] Other effector molecules may include detectable substances useful for example in diagnosis. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive nuclides, positron emitting metals (for use in positron emission tomography), and nonradioactive paramagnetic metal ions. See generally U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics. Suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; suitable prosthetic groups include streptavidin, avidin and biotin; suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride and phycoerythrin; suitable luminescent materials include luminol; suitable bioluminescent materials include luciferase, luciferin, and aequorin; and suitable radioactive nuclides include ^{125}I , ^{131}I , ^{111}In and ^{99}Tc .

[0029] Synthetic or naturally occurring polymers for use as effector molecules include, for example optionally substituted straight or branched chain polyalkylene, polyalkenylene, or polyoxyalkylene polymers or branched or unbranched polysaccharides, e.g. a homo- or hetero- polysaccharide such as lactose, amylose, dextran or glycogen.

[0030] Particular optional substituents which may be present on the above-mentioned synthetic polymers include one or more hydroxy, methyl or methoxy groups. Particular examples of synthetic polymers include optionally substituted straight or branched chain poly(ethyleneglycol), poly(propyleneglycol), poly(vinylalcohol) or derivatives thereof, especially optionally substituted poly(ethyleneglycol) such as methoxypoly(ethyleneglycol) or derivatives thereof.

[0031] "Derivatives" as used herein is intended to include reactive derivatives, for example thiol-selective reactive groups such as an α -halocarboxylic acid or ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl sulphone or disulphide maleimides and the like. The reactive group may be linked directly or through a linker segment to the polymer. It will be appreciated that the residue of such a group will in some instances form part of the product as the linking group between the antibody fragment and the polymer.

[0032] The size of the polymer may be varied as desired, but will generally be in an average molecular weight range from 500Da to 50,000Da, preferably from 5,000 to 40,000Da and more preferably from 10,000 to 40,000Da and 20,000 to 40,000Da. The polymer size may in particular be selected on the basis of the intended use of the product for example ability to localize to certain tissues such as tumors or extend circulating half-life (for review see Chapman, 2002, Advanced Drug Delivery Reviews, 54, 531-545). Thus, for example, where the product is intended to leave the circulation and penetrate tissue, for example for use in the treatment of a tumor, it may be advantageous to use a small molecular weight polymer, for example with a molecular weight of around 5,000Da. For applications where the product remains in the circulation, it may be advantageous to use a higher molecular weight polymer, for example having a molecular weight in the range from 20,000Da to 40,000Da.

[0033] Particularly preferred polymers include a polyalkylene polymer, such as a poly(ethyleneglycol) or, especially, a methoxypoly(ethyleneglycol) or a derivative thereof, and especially with a molecular weight in the range from about 10,000Da to about 40,000Da.

[0034] The polymers of the present invention may be obtained commercially (for example from Nippon Oil and Fats; Nektar Therapeutics) or may be prepared from commercially available starting materials using conventional chemical procedures.

[0035] Effector molecules may be attached using standard chemical or recombinant DNA procedures in which the antibody fragment is linked either directly or via a coupling agent to the effector molecule. Techniques for conjugating such effector molecules to antibodies are well known in the art (see, Hellstrom et al., Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., 1987, pp. 623-53; Thorpe et al., 1982, Immunol. Rev., 62:119-58 and Dubowchik et al., 1999, Pharmacology and Therapeutics, 83, 67-123). Particular chemical procedures include for example those described in International Patent Specification numbers WO 93/06231, WO92/22583, WO90/09195, WO89/01476, WO915549 and WO03031581. Alternatively, where the effector molecule is a protein or polypeptide the linkage may be achieved using recombinant DNA procedures, for example as described in European Patent Specification No. 392745.

[0036] The effector molecules may be attached to the antibody fragment of the present invention through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. Such amino acids may occur naturally in the antibody fragment or may be engineered into the fragment using recombinant DNA methods. See for example US 5,219,996. Preferably effector molecules are covalently linked through a thiol group of a cysteine residue located in the antibody fragment, either

naturally or engineered. The covalent linkage will generally be a disulphide bond or, in particular, a sulphur-carbon bond. Where a thiol group is used as the point of attachment appropriately activated effector molecules, for example thiol selective derivatives such as maleimides and cysteine derivatives may be used.

[0037] It will be appreciated that where there are two or more effector molecules attached to the antibody fragment these may be identical or different and may be attached to the antibody fragment at different sites. It will also be appreciated that two or more effector molecules may be attached to the antibody fragment at a single site by the use for example of a branched connecting structure to link two or more effector molecules and provide a single site of attachment.

[0038] In a preferred aspect of the present invention at least one of the effector molecules attached to the antibody fragment is a polymer molecule, preferably PEG or a derivative thereof. As regards attaching poly(ethyleneglycol) (PEG) moieties in general, reference is made to "Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications", 1992, J. Milton Harris (ed), Plenum Press, New York; "Poly(ethyleneglycol) Chemistry and Biological Applications", 1997, J. Milton Harris and S. Zalipsky (eds), American Chemical Society, Washington DC and "Bioconjugation Protein Coupling Techniques for the Biomedical Sciences", 1998, M. Aslam and A. Dent, Grove Publishers, New York.

[0039] Preferably all the effector molecules attached to the Fab fragment of the present invention are PEG and each molecule is covalently linked via a maleimide group to one or more thiol groups in the antibody fragment. The PEG may be any straight or branched molecule in an average molecular weight range from 500Da to 50,000Da, preferably from 5,000 to 40,000Da and more preferably from 10,000 to 40,000Da and 20,000 to 40,000Da. To attach branched PEG molecules, a lysine residue is preferably covalently linked to the maleimide group. To each of the amine groups on the lysine residue is preferably attached a methoxypoly(ethyleneglycol) polymer. In one example the molecular weight of each polymer attached to the lysine is approximately 20,000Da and the total molecular weight of the entire polymer molecule is therefore approximately 40,000Da. Preferably the PEG molecules attached to the Fab fragment of the present invention are linear.

[0040] One or more effector molecules may be attached to the antibody Fab fragment of the present invention. In a preferred aspect at least two effector molecules are attached to the Fab fragment, one to a cysteine in the light chain constant region and one to a cysteine in the heavy chain constant region. Preferably the cysteine residues to which the effector molecules are attached would otherwise be linked to each other by a disulphide bond if the effector molecules were not attached. Suitable cysteines for attachment include naturally occurring cysteines present in the light and/or heavy chain constant region such as the interchain cysteines. In a preferred aspect of the invention an effector molecule is attached to the interchain cysteine of C_L and the interchain cysteine of C_H1 in the antibody Fab fragment. In one embodiment the interchain cysteine of C_L to which an effector molecule is attached is at position 214 of the light chain and the interchain cysteine of C_H1 to which an effector molecule is attached is at position 233 of the heavy chain. In another embodiment where the constant regions are derived from murine IgG1, the interchain cysteine of C_L to which an effector molecule is attached is at position 214 of the light chain and the interchain cysteine of C_H1 to which an effector molecule is attached is at position 235 of the heavy chain. Other suitable cysteines include those that have been engineered into the constant regions using recombinant DNA techniques. For example two cysteines may be engineered into the antibody fragment, one in each of the heavy and light chain constant regions, preferably at positions whereby they can form a disulphide linkage with each other.

[0041] Particular fragments according to this aspect of the invention include those where:

- (i) the cysteine residues in the heavy and light chain constant regions which are attached to effector molecules would otherwise be linked to each other via a disulphide bond if the effector molecules were not attached or
- (ii) the light chain cysteine to which an effector molecule is attached is the interchain cysteine of C_L and the heavy chain cysteine to which an effector molecule is attached is the interchain cysteine of C_H1

[0042] During attachment of effector molecules to cysteines in the antibody Fab fragment of the present invention any covalent linkages between the cysteines are removed, as described herein, using a reducing agent. In such fragments the heavy chain is no longer covalently bonded to the light chain and the disulphide linkage found in naturally occurring antibodies between the interchain cysteine of C_L and the interchain cysteine of C_H1 is absent.

[0043] Also provided by the present invention therefore is a method for attaching effector molecules to the antibody Fab fragments of the present invention, said method comprising:

- a) Treating an antibody Fab fragment of the present invention with a reducing agent capable of generating a free thiol group in a cysteine of the heavy and light chain constant region
- b) Reacting the treated fragment with an effector molecule

[0044] In a preferred aspect the method comprises:

- a) Reducing the interchain disulphide bond between the interchain cysteine of C_H1 and the interchain cysteine of C_L in the antibody Fab fragment of the present invention
- b) Reacting the treated fragment with an effector molecule

[0045] The methods provided by the present invention enable one or more effector molecule(s) to be attached to cysteines in the antibody fragment, in particular to cysteines in the constant region. Two or more effector molecules can be attached to the antibody fragment using the methods described herein either simultaneously or sequentially by repeating the method.

[0046] Additional effector molecules may be attached elsewhere in the antibody fragment, in particular the constant regions. The methods of the present invention therefore also extend to one or more steps before and/or after the reduction methods described above in which further effector molecules are attached to the antibody fragment using any suitable method as described previously, for example via other available amino acids side chains such as amino and imino groups.

[0047] The reducing agent for use in the methods of the present invention is any reducing agent capable of reducing cysteines in the antibody Fab fragment of the present invention to produce free thiols. Preferably the reducing agent reduces the interchain disulphide bond between cysteines of the heavy and light chain constant regions, for example, between the interchain cysteine of C_L and the interchain cysteine of C_H1, in order to allow attachment of effector molecules to said cysteines. As the antibody Fab fragments of the present invention surprisingly have no requirement for the interchain disulphide bond stronger reducing agents can be used than are conventionally used with wild type antibody fragments which retain the interchain disulphide bond. As a result a higher number of Fab molecules with free thiols are produced and a higher proportion of the antibody fragments are correctly modified i.e. the correct number of effector molecules are attached. In addition, the terminal interchain cysteine of C_H1 in the antibody Fab fragments of the present invention is more highly accessible for effector molecule attachment and reduction than in conventional Fab fragments where there may be steric or local electrostatic effects due to the presence of the upper hinge or other amino acids C-terminal to the C_H1 interchain cysteine. The antibody fragments of the present invention can therefore be modified more efficiently and cost effectively than conventional antibody fragments. It will be clear to a person skilled in the art that suitable reducing agents may be identified by determining the number of free thiols produced after the antibody fragment is treated with the reducing agent. Methods for determining the number of free thiols are well known in the art, see for example Lyons *et al.*, 1990, Protein Engineering, 3, 703. Reducing agents for use in the present invention are widely known in the art for example those described in Singh *et al.*, 1995, Methods in Enzymology, 251, 167-73. Particular examples include thiol based reducing agents such as reduced glutathione (GSH), β -mercaptoethanol (β -ME), (β -mercaptoethylamine (β -MA) and dithiothreitol (DTT). Other methods for reducing the antibody fragments of the present invention include using electrolytic methods, such as the method described in Leach *et al.*, 1965, Div. Protein. Chem, 4, 23-27 and using photoreduction methods, such as the method described in Ellison *et al.*, 2000, Biotechniques, 28 (2), 324-326. Preferably however, the reducing agent for use in the present invention is a non-thiol based reducing agent capable of liberating one or more thiols in an antibody fragment. Preferably the non-thiol based reducing agent is capable of liberating the interchain thiols in an antibody fragment. Preferred reducing agents for use in the present invention are trialkylphosphine reducing agents (Ruegg UT and Rudinger, J., 1977, Methods in Enzymology, 47, 111-126; Bums J *et al.*, 1991, J.Org.Chem, 56, 2648-2650; Getz *et al.*, 1999, Analytical Biochemistry, 273, 73-80; Han and Han, 1994, Analytical Biochemistry, 220, 5-10; Seitz *et al.*, 1999, Euro.J.Nuclear Medicine, 26, 1265-1273), particular examples of which include tris(2-carboxyethyl)phosphine (TCEP), tris butyl phosphine (TBP), tris-(2-cyanoethyl) phosphine, tris-(3-hydroxypropyl) phosphine (THP) and tris-(2-hydroxyethyl) phosphine. Most preferably the reducing agent for use in the present invention is either TCEP or THP. It will be clear to a person skilled in the art that the concentration of reducing agent for use in the present invention can be determined empirically, for example, by varying the concentration of reducing agent and measuring the number of free thiols produced. Typically the reducing agent for use in the present invention is used in excess over the antibody fragment for example between 2 and 1000 fold molar excess. Preferably the reducing agent is in 2, 3, 4, 5, 10, 100 or 1000 fold excess. In one embodiment the reductant is used at between 2 and 5mM.

[0048] The modified antibody Fab fragments according to the invention may be prepared by reacting an antibody Fab fragment as described herein containing at least one reactive cysteine residue with an effector molecule, preferably a thiol-selective activated effector molecule. The reactions in steps (a) and (b) of the method described above may generally be performed in a solvent, for example an aqueous buffer solution such as acetate or phosphate, at around neutral pH, for example around pH 4.5 to around pH 8.5, typically pH 4.5 to 8, suitably pH6 to 7. The reaction may generally be performed at any suitable temperature, for example between about 5°C and about 70°C, for example at room temperature. The solvent may optionally contain a chelating agent such as EDTA, EGTA, CDTA or DTPA. Preferably the solvent contains EDTA at between 1 and 5mM, preferably 2mM. Alternatively or in addition the solvent may be a chelating buffer such as citric acid, oxalic acid, folic acid, bicine, tricine, tris or ADA. The effector molecule will generally be employed in excess concentration relative to the concentration of the antibody fragment. Typically the effector molecule is in between 2 and 100 fold molar excess, preferably 5, 10 or 50 fold excess.

[0049] Where necessary, the desired product containing the desired number of effector molecules may be separated

from any starting materials or other product generated during the production process by conventional means, for example by chromatography techniques such as ion exchange, size exclusion, protein A, G or L affinity chromatography or hydrophobic interaction chromatography.

[0050] Also provided by the present invention is a mixture containing two or more antibody Fab fragments, characterized in that the mixture is enriched for Fab fragments in which the heavy chain constant domain terminates at the interchain cysteine of C_H1, the heavy chains in the fragments are not covalently bonded to the light chains and the fragments have an effector molecule attached to a cysteine in the light chain and the heavy chain constant region. Said mixture may be produced using the methods provided by the present invention. By 'enriched' we mean that the antibody Fab fragment with the desired number of effector molecules attached accounts for 50% or greater of the mixture. Preferably the antibody Fab fragment with the desired number of effector molecules attached accounts for between 50 and 99% of the mixture. Preferably the mixtures are enriched by greater than 50%, preferably greater than 60%, more preferably greater than 70%. The proportion of such mixtures containing the antibody Fab fragment with the desired number of effector molecules may be determined by using the size exclusion HPLC methods described herein.

[0051] The antibody fragments according to the invention may be useful in the detection or treatment of a number of diseases or disorders. Such diseases or disorders may include those described under the general heading of infectious disease, e.g. bacterial infection; fungal infection; inflammatory disease/autoimmunity e.g. rheumatoid arthritis, osteoarthritis, inflammatory bowel disease; cancer; allergic/atopic disease e.g. asthma, eczema; congenital disease; e.g. cystic fibrosis, sickle cell anemia; dermatologic disease e.g. psoriasis; neurologic disease, e.g. multiple sclerosis; transplants e.g. organ transplant rejection, graft-versus-host disease; and metabolic/idiopathic disease e.g. diabetes.

[0052] The antibody fragments according to the invention may be formulated for use in therapy and/or diagnosis and according to a further aspect of the invention we provide a pharmaceutical composition comprising an antibody Fab fragment in which the heavy chain constant region terminates at the interchain cysteine of C_H1 together with one or more pharmaceutically acceptable excipients, diluents or carriers. Also provided is a pharmaceutical composition comprising an antibody Fab fragment in which the heavy chain constant region terminates at the interchain cysteine of C_H1, the heavy chain is not covalently bonded to the light chain and the fragment has an effector molecule attached to a cysteine in the light chain and the heavy chain constant region, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

EXAMPLES

[0053] The present invention will now be described by way of example only, in which reference is made to:

Figure 1: Non-reducing SDS-PAGE of PEGylated g163 Fab in which the heavy chain constant region terminates at the interchain cysteine of C_H1. Lane B shows g163 Fab with PEG attached following reduction with TCEP. Lane D shows g163 Fab with PEG attached following reduction with THP.

Figure 2: Comparison of the reductants THP and TCEP on the PEGylation efficiency of Fab(B).

Figure 3: SDS-PAGE of PEGylated murine Fab, m13.

Figure 4: Pharmacokinetics of ¹²⁵I labelled m13 Fab-DiPEG(2x20kDa) in mice.

Example 1 Creation of a novel 'truncated' Fab fragment.

[0054] The antibody Fab molecule in Example 2 was g163 which binds to baboon platelet-derived growth factor receptor (PDGFr). The antibody Fab molecule in Examples 3-6 was a human Fab (herein after referred to as FAB(B)) which binds a soluble cytokine. The antibody Fab molecule in Examples 7-8 was a murine Fab, m13, which binds a soluble cytokine. To produce g163 and Fab(B) PCR primers were designed based on the human IgG1 C_H1 region and PCR mutagenesis used to insert a stop codon immediately following the interchain cysteine of C_H1. To produce m13 PCR primers were designed based on the murine IgG1 CH1 region and PCR mutagenesis used to insert a stop codon immediately following the interchain cysteine of C_H1. The sequences of the heavy and light chain constant regions are shown below and in Figure 5:

Wild type Human γ 1 Fab constant regions:

[0055]

Kappa (Seq ID NO:2)

KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
VTEQDSKDSITYSLSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC*

5

CH1 (Seq ID NO:9)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCAA*

10

[0056] Human 'truncated' γ 1 Fab constant regions used in g163 and Fab(B):

15

Kappa (Seq ID NO:2)

KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
VTEQDSKDSITYSLSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC*

20

CH1 (SEQ ID NO:1)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC*

25

[0057] Murine 'truncated' γ 1 Fab constant regions used in m13:

30

Kappa (SEQ ID NO:4)

DAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSRQNGVLNSWTDQ
DSKDSITYSMSSTLTLTKEDEYERHNSYTCEATHKTSTSPIVKSFNRGEC*

35

CH1(SEQ ID NO:3)

KTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVL
QSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDC*

40

[0058] The underlined cysteine residues indicate the interchain cysteines to which effector molecules may be attached.

[0059] The Fab fragments were produced in *E.coli* strain W3110 and purified using standard methods (Humphreys et al., 2002, Protein Expression and Purification, 26, 309-320).

45

Example 2: PEGylation of g163

[0060] All reductions and PEGylations were performed in 0.1M Phosphate pH6.0; 2mM EDTA. The concentration of Fab was 5mg/ml and reductant was at 40mM final concentration. In all cases reduction was performed at room temperature (~24°C) for 30 minutes, the proteins desalted on a PD-10 column (Pharmacia) and then mixed with 5 fold molar excess of 20kDa PEG-maleimide over Fab. The 20 kDa PEG was from Nippon Oils and Fats (NOF). PEGylated Fab was separated from unPEGylated Fab by size exclusion HPLC on analytical Zorbax GF-450 and GF-250 columns in series. These were developed with a 30min isocratic gradient of 0.2M phosphate pH 7.0 + 10% ethanol at 1ml/min and Fab detected using absorbance at 214nm and 280nm.

55

[0061] The g163 Fab was reduced using two non thiol based reducing agents, tris(2-carboxyethyl)phosphine (TCEP), tris butyl phosphine (TBP) and two 20kDa PEG molecules attached to the interchain cysteines. PEGylation was expected to occur on both cysteines if the inter-chain disulphide was reduced. The PEGylation of both sites was confirmed by

non-reducing SDS-PAGE (Figure 1). Lane B corresponds to g163 truncated Fab with two PEG molecules attached following reduction with TCEP. The two high molecular weight bands very close together around 100kDa are composed of heavy and light chain with one PEG molecule attached. The lower band at around 45kDa is a small amount of unmodified Fab with no PEG attached. The lower band at around 25kDa is free heavy and light chains. Lane D is the same fragment reduced using TBP that is less compatible with aqueous buffers and proteins. The percentage of the g163 truncated Fab to be diPEGylated using TCEP and TBP as reductants was 76% and 21% respectively, as determined by HPLC. TCEP is therefore a useful reducing agent for producing the modified antibody fragments of the present invention.

Example 3: Comparison of efficiency of PEGylation of Fab(B) using the reducing agents TCEP and THP

[0062] In this example reductions and PEGylations were conducted in 50mM MOPS, 2mM EDTA pH6.8. Reduction of Fab(B) (20mg/ml) was performed using reducing agents TCEP or THP at 10mM, for 1hr at ambient temperature. Reductant was removed on PD10 desalting columns (Pharmacia) with a stringent cut to prevent carry over of the reductant. PEGylation was conducted using 3 fold molar excess of 20kDa PEG-maleimide over Fab, over night at ambient temperature. Figure 2 shows that THP is also a useful reducing agent for attaching PEG to the antibody fragments of the present invention.

Example 4: Di-Pegylation of a murine Fab, m13.

[0063] The interchain cysteines of a murine truncated Fab, m13 were PEGylated using 20kDa linear PEG. Reductions and PEGylations were performed in 50mM Tris.HCl 5mM EDTA pH 7.14 with Fab at 20.06mg/ml, 10mM TCEP (final) and 4 molar excess of 20kDa linear PEG, room temperature. The PEGylation of both sites was confirmed by SDS-PAGE (Figure 3). Lane 1 m13 diPEGylated (non-reduced); Lane 2 m13 diPEGylated reduced; Lane 3 m13 non-reduced (no PEG); Lane 4 m13 reduced (no PEG).

Example 5: Pharmacokinetics of m13 Fab-PEG (2x20kDa) in mice.

[0064] The circulating half life of m13Fab PEGylated on both polypeptides (as in Example 4) in animals was determined. ¹²⁵I labelled PEGylated Fab molecules were injected subcutaneously or intravenously into mice and the serum permanence determined.

[0065] Mice were injected subcutaneously on the back of the neck or intravenously in the tail vein under light anaesthesia. The injection volume was 100 μ l per mouse which was equivalent to 13 μ g protein and 1.2 μ Ci isotope dose (specific activity (0.1 μ Ci/ μ g). 4 mice were bled by cardiac puncture at each time point. Heparanised blood was collected in preweighed tubes. The weight of the blood was determined before counting for radioactivity in the gamma counter. Time points studied:

iv; 0.5, 2, 4, 6, 24, 48, 72 and 144h post injection.
sc; 3,6,24, 30, 48, 72 and 144h post injection.

Table 1.

	IV	SC
AUC (0-∞) (%dose*h)	3147	2072
T_{1/2} β(h)	37	41
Cmax(%dose)		26

[0066] The results in Table 1 and Figure 4 show that although the heavy and light chains in the PEGylated Fab are non-covalently associated the circulating half life is higher than a non-PEGylated Fab ($t_{1/2} \approx 30$ minutes) and that of free LC or HC which is likely to be shorter still.

Claims

1. An antibody Fab fragment **characterized in that** the heavy chain constant region terminates at the interchain

cysteine of C_H1.

2. The antibody Fab fragment of claim 1 in which the interchain cysteine of C_H1 is covalently linked to the interchain cysteine of C_L.
3. The antibody Fab fragment of claim 1 or claim 2 in which the interchain cysteine of C_H1 is at position 233 of the heavy chain.
4. The antibody Fab fragment of claim 1 or claim 2 in which the interchain cysteine of C_H1 is at position 127 of the heavy chain.
5. The antibody Fab fragment of claim 1 or claim 2 in which the interchain cysteine of C_H1 is at position 128 of the heavy chain.
6. The antibody Fab fragment of claim 1 or claim 2 in which the interchain cysteine of C_H1 is at position 235 of the heavy chain.
7. The antibody Fab fragment of claims 1-5 in which the interchain cysteine of the light chain constant region is at position 214 of the light chain.
8. The antibody Fab fragment of claims 1-3 in which the heavy chain constant region consists of a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO:1.
9. The antibody Fab fragment of claim 8 in which the light chain constant region consists of a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO:2.
10. The antibody Fab fragment of claims 1, 2 and 6 in which the heavy chain constant region consists of a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO:3.
11. The antibody Fab fragment of claim 10 in which the light chain constant region consists of a sequence having at least 90% identity or similarity to the sequence given in SEQ ID NO:4.
12. The antibody Fab fragment of claims 1 to 11 to which one or more effector molecules are attached.
13. The antibody Fab fragment of claim 12 to which two or more effector molecules are attached.
14. The antibody fragment of claim 13, wherein an effector molecule is attached to a cysteine in the light chain constant region and a cysteine in the heavy chain constant region.
15. The antibody fragment of claim 14, wherein the cysteine residues in the heavy and light chain constant regions which are attached to effector molecules would otherwise be linked to each other via a disulphide bond if the effector molecules were not attached.
16. The antibody fragment of claim 15 where the light chain cysteine to which an effector molecule is attached is the interchain cysteine of C_L and the heavy chain cysteine to which an effector molecule is attached is the interchain cysteine of C_H1.
17. The antibody Fab fragment of claims 12-16 wherein the effector molecule is PEG
18. A method of producing an antibody Fab fragment according to claims 12-17 comprising:
 - a. Treating an antibody Fab fragment according to claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 with a reducing agent capable of generating a free thiol group in a cysteine of the heavy and light chain constant region
 - b. Reacting the treated fragment with an effector molecule
19. The method according to claim 18 in which the reducing agent is a non-thiol based reductant.
20. The method according to claim 19 in which the reductant is a trialkylphosphine.

21. The method according to claim 20 where the non-thiol based reductant is tris(2-carboxyethyl)phosphine (TCEP).
22. The method according to claim 20 where the non-thiol based reductant is tris(3-hydroxypropyl)phosphine (THP).
- 5 23. The method according to claim 18 in which either or both of steps (a) and (b) are performed in the presence of a chelating agent.
24. The method according to claim 23 in which the chelating agent is EDTA.
- 10 25. The method according to claim 24 in which both steps (a) and (b) are performed in the presence of EDTA.
26. A mixture containing two or more antibody Fab fragments, **characterized in that** the mixture is enriched for Fab fragments in which the C_H1 domain terminates at the interchain cysteine, the heavy chains in the fragments are not covalently bonded to the light chains and the fragments have an effector molecule attached to a cysteine in the light chain and the heavy chain constant region.
- 15 27. The mixture of claim 26 in which greater than 50% of the mixture comprises a Fab fragment in which the C_H1 domain terminates at the interchain cysteine, the heavy chains in the fragments are not covalently bonded to the light chains and the fragments have an effector molecule attached to a cysteine in the light chain and the heavy chain constant region.
- 20 28. An isolated DNA sequence encoding the heavy and/or light chain constant regions of an antibody Fab fragment according to any one of claims 3-11.
- 25 29. A cloning or expression vector comprising one or more DNA sequences according to claim 28.
30. The vector according to claim 29, wherein the vector comprises the sequence given in SEQ ID NO:5.
31. The vector according to claim 30 further comprising the sequence given in SEQ ID NO:6.
- 30 32. The vector according to claim 29, wherein the vector comprises the sequence given in SEQ ID NO:7.
33. The vector according to claim 32 further comprising the sequence given in SEQ ID NO:8.
- 35 34. A host cell expressing the antibody Fab fragment of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11
35. A host cell according to claim 34 comprising one or more cloning or expression vectors according to claims 29-33.
- 40 36. A process for producing the antibody Fab fragment of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 comprising culturing the host cell of claim 34 and isolating said fragment.
37. A pharmaceutical composition comprising an antibody Fab fragment according to claims 1-17 and 26-27, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

Patentansprüche

1. Antikörper-Fab-Fragment, **dadurch gekennzeichnet, dass** die konstante Region der schweren Kette am Interketten-Cystein der C_H1 endet.
- 50 2. Antikörper-Fab-Fragment nach Anspruch 1, wobei das Interketten-Cystein der C_H1 kovalent mit dem Interketten-Cystein der C_L verknüpft ist.
3. Antikörper-Fab-Fragment nach Anspruch 1 oder Anspruch 2, wobei das Interketten-Cystein der C_H1 sich an Position 233 der schweren Kette befindet.
- 55 4. Antikörper-Fab-Fragment nach Anspruch 1 oder Anspruch 2, wobei das Interketten-Cystein der C_H1 sich an Position 127 der schweren Kette befindet.

5. Antikörper-Fab-Fragment nach Anspruch 1 oder Anspruch 2, wobei das Interketten-Cystein der C_H1 sich an Position 128 der schweren Kette befindet.
- 5 6. Antikörper-Fab-Fragment nach Anspruch 1 oder Anspruch 2, wobei das Interketten-Cystein der C_H1 sich an Position 235 der schweren Kette befindet.
7. Antikörper-Fab-Fragment nach den Ansprüchen 1-5, wobei das Interketten-Cystein der konstanten Region der leichten Kette sich an Position 214 der leichten Kette befindet.
- 10 8. Antikörper-Fab-Fragment nach den Ansprüchen 1-3, wobei die konstante Region der schweren Kette aus einer Sequenz mit mindestens 90% Identität oder Ähnlichkeit zu der in SEQ ID NO: 1 angegebenen Sequenz besteht.
9. Antikörper-Fab-Fragment nach Anspruch 8, wobei die konstante Region der leichten Kette aus einer Sequenz mit mindestens 90% Identität oder Ähnlichkeit zu der in SEQ ID NO: 2 angegebenen Sequenz besteht.
- 15 10. Antikörper-Fab-Fragment nach den Ansprüchen 1, 2 und 6, wobei die konstante Region der schweren Kette aus einer Sequenz mit mindestens 90% Identität oder Ähnlichkeit zu der in SEQ ID NO: 3 angegebenen Sequenz besteht.
11. Antikörper-Fab-Fragment nach Anspruch 10, wobei die konstante Region der leichten Kette aus einer Sequenz mit mindestens 90% Identität oder Ähnlichkeit zu der in SEQ ID NO: 4 angegebenen Sequenz besteht.
- 20 12. Antikörper-Fab-Fragment nach den Ansprüchen 1 bis 11, an das ein oder mehrere Effektormoleküle gebunden sind.
13. Antikörper-Fab-Fragment nach Anspruch 12, an das zwei oder mehrere Effektormoleküle gebunden sind.
- 25 14. Antikörperfragment nach Anspruch 13, wobei ein Effektormolekül an ein Cystein in der konstanten Region der leichten Kette und ein Cystein in der konstanten Region der schweren Kette gebunden ist.
15. Antikörperfragment nach Anspruch 14, wobei die Cysteinreste in den konstanten Regionen der schweren und leichten Kette, die an Effektormoleküle gebunden sind, ansonsten über eine Disulfidbindung aneinander gebunden wären, wenn die Effektormoleküle nicht gebunden wären.
- 30 16. Antikörperfragment nach Anspruch 15, wobei es sich bei dem leichten Kette-Cystein, an das ein Effektormolekül gebunden ist, um das Interketten-Cystein der C_L handelt und bei dem schweren Kette-Cystein, an das ein Effektormolekül gebunden ist, um das Interketten-Cystein der C_H1 handelt.
- 35 17. Antikörper-Fab-Fragment nach den Ansprüchen 12-16, wobei das Effektormolekül PEG ist.
18. Verfahren zur Herstellung eines Antikörper-Fab-Fragments nach den Ansprüchen 12-17, umfassend
- 40 a. Behandeln eines Antikörper-Fab-Fragments nach den Ansprüchen 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 oder 11 mit einem Reduktionsmittel, das in der Lage ist, eine freie Thiolgruppe in einem Cystein der konstanten Region der schweren und der leichten Kette zu erzeugen
- b. Umsetzen des behandelten Fragments mit einem Effektormolekül
- 45 19. Verfahren nach Anspruch 18, wobei es sich bei dem Reduktionsmittel um ein nicht auf Thiol basierendes Reduktionsmittel handelt.
20. Verfahren nach Anspruch 19, wobei das Reduktionsmittel ein Trialkylphosphin ist.
- 50 21. Verfahren nach Anspruch 20, wobei das nicht auf Thiol basierende Reduktionsmittel Tris(2-carboxyethyl)phosphin (TCEP) ist.
22. Verfahren nach Anspruch 20, wobei das nicht auf Thiol basierende Reduktionsmittel Tris(3-hydroxypropyl)phosphin (THP) ist.
- 55 23. Verfahren nach Anspruch 18, wobei einer oder beide der Schritte (a) und (b) in Gegenwart eines Chelatbildners durchgeführt werden.

24. Verfahren nach Anspruch 23, wobei der Chelatbildner EDTA ist.

25. Verfahren nach Anspruch 24, wobei beide Schritte (a) und (b) in Gegenwart von EDTA durchgeführt werden.

5 26. Gemisch, enthaltend zwei oder mehrere Antikörper-Fab-Fragmente, **dadurch gekennzeichnet, dass** das Gemisch an Fab-Fragmenten angereichert ist, in denen die C_H1 -Domäne am Interketten-Cystein endet, die schweren Ketten in den Fragmenten nicht kovalent an die leichten Ketten gebunden sind und die Fragmente ein an ein Cystein in der konstanten Region der leichten Kette und der schweren Ketten gebundenes Effektormolekül besitzen.

10 27. Gemisch nach Anspruch 26, wobei mehr als 50% des Gemischs ein Fab-Fragment umfassen, in dem die C_H1 -Domäne am Interketten-Cystein endet, die schweren Ketten in den Fragmenten nicht kovalent an die leichten Ketten gebunden sind und die Fragmente ein an ein Cystein in der konstanten Region der leichten Kette und der schweren Ketten gebundenes Effektormolekül besitzen.

15 28. Isolierte DNA-Sequenz, die die konstanten Regionen der schweren und/oder leichten Kette eines Antikörper-Fab-Fragments nach einem der Ansprüche 3-11 codiert.

29. Klonierungs- oder Expressionsvektor, umfassend eine oder mehrere DNA-Sequenzen nach Anspruch 28.

20 30. Vektor nach Anspruch 29, wobei der Vektor die in SEQ ID NO: 5 angegebene Sequenz umfasst.

31. Vektor nach Anspruch 30, der zudem die in SEQ ID NO: 6 angegebene Sequenz umfasst.

25 32. Vektor nach Anspruch 29, wobei der Vektor die in SEQ ID NO: 7 angegebene Sequenz umfasst.

33. Vektor nach Anspruch 32, der zudem die in SEQ ID NO: 8 angegebene Sequenz umfasst.

34. Wirtszelle, die das Antikörper-Fab-Fragment nach Anspruch 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 oder 11 exprimiert.

30 35. Wirtszelle nach Anspruch 34, umfassend einen oder mehrere Klonierungs- oder Expressionsvektoren nach den Ansprüchen 29-33.

36. Verfahren zur Herstellung des Antikörper-Fab-Fragments nach Anspruch 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 oder 11, umfassend das Züchten der Wirtszelle nach Anspruch 34 und Isolieren des Fragments.

35 37. Pharmazeutische Zusammensetzung, umfassend ein Antikörper-Fab-Fragment nach den Ansprüchen 1-17 und 26-27 zusammen mit einem oder mehreren pharmazeutisch annehmbaren Excipienten, Verdünnungsmitteln oder Trägern.

40 Revendications

1. Fragment Fab d'anticorps **caractérisé en ce que** la région constante de chaîne lourde termine à la cystéine interchaîne de C_H1 .

45 2. Fragment Fab d'anticorps de la revendication 1 dans lequel la cystéine interchaîne de C_H1 est liée de façon covalente à la cystéine interchaîne de C_L .

50 3. Fragment Fab d'anticorps de la revendication 1 ou la revendication 2 dans lequel la cystéine interchaîne de C_H1 est à la position 233 de la chaîne lourde.

4. Fragment Fab d'anticorps de la revendication 1 ou la revendication 2 dans lequel la cystéine interchaîne de C_H1 est à la position 127 de la chaîne lourde.

55 5. Fragment Fab d'anticorps de la revendication 1 ou la revendication 2 dans lequel la cystéine interchaîne de C_H1 est à la position 128 de la chaîne lourde.

6. Fragment Fab d'anticorps de la revendication 1 ou la revendication 2 dans lequel la cystéine interchaîne de C_H1

est à la position 235 de la chaîne lourde.

7. Fragment Fab d'anticorps des revendications 1 à 5 dans lequel la cystéine interchaîne de la région constante de chaîne légère est à la position 214 de la chaîne légère.
8. Fragment Fab d'anticorps des revendications 1 à 3 dans lequel la région constante de chaîne lourde est constituée d'une séquence ayant au moins 90 % d'identité ou similarité à la séquence décrite dans SEQ ID NO: 1.
9. Fragment Fab d'anticorps de la revendication 8 dans lequel la région constante de chaîne légère est constituée d'une séquence ayant au moins 90 % d'identité ou similarité à la séquence décrite dans SEQ ID NO: 2.
10. Fragment Fab d'anticorps des revendications 1, 2 et 6 dans lequel la région constante de chaîne lourde est constituée d'une séquence ayant au moins 90 % d'identité ou de similarité à la séquence décrite dans SEQ ID NO: 3.
11. Fragment Fab d'anticorps de la revendication 10 dans lequel la région constante de chaîne légère est constituée d'une séquence ayant au moins 90 % d'identité ou similarité à la séquence décrite dans SEQ ID NO: 4.
12. Fragment Fab d'anticorps des revendications 1 à 11 auquel une ou plusieurs molécules effectrices sont liées.
13. Fragment Fab d'anticorps de la revendication 12 auquel deux molécules effectrices ou plus sont liées.
14. Fragment d'anticorps de la revendication 13, dans lequel une molécule effectrice est liée à une cystéine dans la région constante de chaîne légère et une cystéine dans la région constante de chaîne lourde.
15. Fragment d'anticorps de la revendication 14, dans lequel les résidus cystéine dans les régions constantes de chaîne lourde et légère qui sont liées à des molécules effectrices seraient autrement liées les uns aux autres par l'intermédiaire d'une liaison disulfure si les molécules effectrices n'étaient pas liées.
16. Fragment d'anticorps de la revendication 15 dans lequel la cystéine de chaîne légère à laquelle une molécule effectrice est liée est la cystéine interchaîne de C_L et la cystéine de chaîne lourde à laquelle une molécule effectrice est liée est la cystéine interchaîne de C_H1.
17. Fragment Fab d'anticorps des revendications 12 à 16 dans lequel la molécule effectrice est PEG.
18. Procédé de production d'un fragment Fab d'anticorps selon les revendications 12 à 17 comprenant :
 - a. traitement d'un fragment Fab d'anticorps selon les revendications 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ou 11 avec un agent réducteur capable de générer un groupe thiol libre dans une cystéine de la région constante de chaîne lourde et légère
 - b. réaction du fragment traité avec une molécule effectrice.
19. Procédé selon la revendication 18 dans lequel l'agent réducteur est un réducteur non à base de thiol.
20. Procédé selon la revendication 19 dans lequel le réducteur est une trialkylphosphine.
21. Procédé selon la revendication 20 dans lequel le réducteur non à base de thiol est la tris(2-carboxyéthyl)phosphine (TCEP).
22. Procédé selon la revendication 20 dans lequel le réducteur non à base de thiol est la tris(3-hydroxypropyl)phosphine (THP).
23. Procédé selon la revendication 18 dans lequel l'une ou les deux étapes (a) et (b) sont conduites en présence d'un agent chélateur.
24. Procédé selon la revendication 23 dans lequel l'agent chélateur est l'EDTA.
25. Procédé selon la revendication 24 dans lequel les deux étapes (a) et (b) sont conduites en présence d'EDTA.

26. Mélange contenant deux fragments Fab d'anticorps ou plus, **caractérisé en ce que** le mélange est enrichi en fragments Fab dans lesquels le domaine C_H1 termine à la cystéine interchaîne, les chaînes lourdes dans les fragments ne sont pas liés de façon covalente aux chaînes légères et les fragments ont une molécule effectrice liée à une cystéine dans la région constante de chaîne légère et de chaîne lourde.

5

27. Mélange de la revendication 26 dans lequel plus de 50 % du mélange comprend un fragment Fab dans lequel le domaine C_H1 termine à la cystéine interchaîne, les chaînes lourdes dans les fragments ne sont pas liés de façon covalente aux chaînes légères et les fragments ont une molécule effectrice liée à une cystéine dans la région constante de chaîne légère et de chaîne lourde.

10

28. Séquence d'ADN isolée codant pour les régions constantes de chaîne lourde et/ou légère d'un fragment Fab d'anticorps selon l'une quelconque des revendications 3 à 11.

29. Vecteur de clonage ou d'expression comprenant une ou plusieurs séquences d'ADN selon la revendication 28.

15

30. Vecteur selon la revendication 29, le vecteur comprenant la séquence décrite dans SEQ ID NO: 5.

31. Vecteur selon la revendication 30 comprenant en outre la séquence décrite dans SEQ ID NO: 6.

20

32. Vecteur selon la revendication 29, le vecteur comprenant la séquence décrite dans SEQ ID NO: 7.

33. Vecteur selon la revendication 32 comprenant en outre la séquence décrite dans SEQ ID NO: 8.

34. Cellule hôte exprimant le fragment Fab d'anticorps de la revendication 1,2, 3, 4, 5, 6, 7, 8, 9,10 ou 11.

25

35. Cellule hôte selon la revendication 34 comprenant un ou plusieurs vecteurs de clonage ou d'expression selon les revendications 29 à 33.

36. Procédé pour produire le fragment Fab d'anticorps de la revendication 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ou 11 comprenant la culture de la cellule hôte de la revendication 34 et l'isolement dudit fragment.

30

37. Composition pharmaceutique comprenant un fragment Fab d'anticorps selon les revendications 1 à 17 et 26 à 27, conjointement avec un ou plusieurs excipients, diluants ou véhicules pharmaceutiquement acceptables.

35

40

45

50

55

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

Seq ID No:1

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC

Seq ID No:2

KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
STYSLSSLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC

Seq ID No: 3

KTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTSL
SSVTVPSSTWTPSETVTCNV AHPASSTKVDKKIVPRDC

Seq ID No:4

DAAPTIVSIFPPSSEQLTSGGASVVCFLNFFYPKDIVKWKIDGSERQNGVLNSWTDQDSKDSTY
SMSSTLTTLTKDEYERHNSYTCETHKTSTSPIVKSFNRGEC

Seq ID No:5

GCTTCTACAAAGGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGGGG
CACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGG
AACTCAGGCGCCCTGACCAGCGGCGTGACACACCTTCCCGGCTGTCCTACAGTCCTCAGGACT
CTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCT
GCAACGTGAATCACAAGCCCAGCAACACCAAGGTCGACAAGAAAGTTGAGCCCAAATCTTG
TTAA

Seq ID No:6

AAACGTACGGTAGCGGCCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATC
TGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGT
GGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACA
GCAAGGACAGCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACTACGAGA
AACACAAAGTCTACGCCTGCGAAGTCAACCATCAGGGCCTGAGCTCACCAGTAACAAAAAG
TTTTAATAGAGGGGAGTGTTAA

Seq ID No.7

AAAACGACACCCCCATCTGTCTATCCACTGGCCCCCTGGATCTGCTGCCCAAACCTAACTCCAT
GGTGACCTGGGATGCCTGGTCAAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAAC
TCTGGATCCCTGTCCAGCGGTGTGCACACCTTCCCGGCTGTCCTGCAATCTGACCTCTACAC
TCTGAGCAGCTCAGTGACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAAC
GTTGCCCAACCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCCAGGGATTGTAA

Seq ID No:8

GATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAACATCTGGAGGTGC
CTCAGTCGTGTGCTTCTTGAACAACTTCTACCCCAAAGACATCAATGTCAAGTGGAAGATTG
ATGGCAGTGAACGACAAAATGGCGTCTGAAACAGTTGGACTGATCAGGACAGCAAAGACA
GCACCTACAGCATGAGCAGCACCTCAGTTGACCAAGGACGAGTATGAACGACATAACAG
CTATACCTGTGAGGCCACTCACAAGACATCAACTTACCCATTGTCAAAGCTTTAATAGAG
GGGAGTGTTAA

Seq ID NO:9

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCAA

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5677425 A [0005]
- WO 9825971 A [0005]
- US 5219996 A [0005] [0036]
- US 4816397 A, Boss [0010]
- US 6331415 B, Cabilly [0010]
- WO 9202551 A, Shrader [0010]
- US 5585089 A, Queen [0010]
- WO 9109967 A, Adair [0010]
- US 5665866 A [0021]
- WO 9222583 A [0026] [0035]
- US 4741900 A [0028]
- WO 9306231 A [0035]
- WO 9009195 A [0035]
- WO 8901476 A [0035]
- WO 9915549 A [0035]
- WO 03031581 A [0035]
- EP 392745 A [0035]

Non-patent literature cited in the description

- TOUT N L et al. *Clinical and Diagnostic Laboratory Immunology*, 1997, vol. 4 (2), 147-155 [0002]
- CHAPMAN A P et al. *Nature Biotechnology*, 1999, vol. 17 (8), 780-783 [0002]
- CHAPMAN et al. *Nature Biotechnology*, 1999, vol. 17, 780-783 [0002] [0005]
- LEONG et al. *Cytokine*, 2001, vol. 16, 106-119 [0002] [0005]
- CHAPMAN. *Advanced Drug Delivery Reviews*, 2002, vol. 54, 531-545 [0002] [0004] [0032]
- BEGG ; SPEICHER. *Journal of Biomolecular techniques*, 1999, vol. 10, 17-20 [0006]
- KABAT et al. *Sequences of Proteins of Immunological Interest*. US Department of Health and Human Services, NIH, USA, 1987 [0009]
- PCR Protocols: Current Methods and Applications. 1993 [0010]
- ORLANDI et al. *Proc.Natl.Acad.Sci. USA*, 1989, vol. 86, 3833 [0010]
- RIECHMANN et al. *Nature*, 1988, vol. 322, 323 [0010]
- MOUNTAIN ; ADAIR. *Biotechnol. Genet. Eng. Rev.*, 1992, vol. 10, 1-142 [0010]
- VERMA et al. *Journal of Immunological Methods*, 1998, vol. 216, 165-181 [0010]
- Computational Molecular Biology. Oxford University Press, 1988 [0015]
- Biocomputing. Informatics and Genome Projects. Academic Press, 1993 [0015]
- Computer Analysis of Sequence Data, Part 1. Humana Press, 1994 [0015]
- VON HEINJE, G. *Sequence Analysis in Molecular Biology*. Academic Press, 1987 [0015]
- Sequence Analysis Primer. M Stockton Press, 1991 [0015]
- Current Protocols in Molecular Biology. Wiley Interscience, 1999 [0020]
- Maniatis Manual. Cold Spring Harbor Publishing [0020]
- HELLSTROM et al. *Controlled Drug Delivery*. 1987, 623-53 [0035]
- THORPE et al. *Immunol. Rev.*, 1982, vol. 62, 119-58 [0035]
- DUBOWCHIK et al. *Pharmacology and Therapeutics*, 1999, vol. 83, 67-123 [0035]
- Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications. Plenum Press, 1992 [0038]
- Poly(ethyleneglycol) Chemistry and Biological Applications. American Chemical Society, 1997 [0038]
- M. ASLAM ; A. DENT. *Bioconjugation Protein Coupling Techniques for the Biomedical Sciences*. Grove Publishers, 1998 [0038]
- SINGH et al. *Methods in Enzymology*, 1995, vol. 251, 167-73 [0047]
- LEACH et al. *Div. Protein. Chem*, 1965, vol. 4, 23-27 [0047]
- ELLISON et al. *Biotechniques*, 2000, vol. 28 (2), 324-326 [0047]
- RUEGG UT ; RUDINGER, J. *Methods in Enzymology*, 1977, vol. 47, 111-126 [0047]
- BUMS J et al. *J.Org.Chem*, 1991, vol. 56, 2648-2650 [0047]
- GETZ et al. *Analytical Biochemistry*, 1999, vol. 273, 73-80 [0047]
- HAN ; HAN. *Analytical Biochemistry*, 1994, vol. 220, 5-10 [0047]
- SEITZ et al. *Euro.J.Nuclear Medicine*, 1999, vol. 26, 1265-1273 [0047]
- HUMPHREYS et al. *Protein Expression and Purification*, 2002, vol. 26, 309-320 [0059]

Szabadalmi igénypontok

1. Fab-ellenanyagfragmens, azzal jellemezve, hogy a nehézlánc konstans régió a C_{H1} -ben lévő láncközi ciszteinnél végződik.
2. Az 1. igénypont szerinti Fab-ellenanyagfragmens, ahol a C_{H1} -ben lévő láncközi cisztein kovalensen hozzá van kötve a C_L -ben lévő láncközi ciszteinhez.
3. Az 1. vagy 2. igénypont szerinti Fab-ellenanyagfragmens, ahol a C_{H1} -ben lévő láncközi cisztein a nehézlánc 233. pozíciójában van.
4. Az 1. vagy 2. igénypont szerinti Fab-ellenanyagfragmens, ahol a C_{H1} -ben lévő láncközi cisztein a nehézlánc 127. pozíciójában van.
5. Az 1. vagy 2. igénypont szerinti Fab-ellenanyagfragmens, ahol a C_{H1} -ben lévő láncközi cisztein a nehézlánc 128. pozíciójában van.
6. Az 1. vagy 2. igénypont szerinti Fab-ellenanyagfragmens, ahol a C_{H1} -ben lévő láncközi cisztein a nehézlánc 235. pozíciójában van.
7. Az 1-5. igénypontok bármelyike szerinti Fab-ellenanyagfragmens, ahol a könnyűlánc konstans régióban lévő láncközi cisztein a könnyűlánc 214. pozíciójában van.
8. Az 1-3. igénypontok bármelyike szerinti Fab-ellenanyagfragmens, ahol a nehézlánc konstans régió SEQ ID NO:1 szerinti szekvenciával legalább 90%-os azonosságú vagy hasonlóságú szekvenciából áll.
9. A 8. igénypont szerinti Fab-ellenanyagfragmens, ahol a könnyűlánc konstans régió SEQ ID NO:2 szerinti szekvenciával legalább 90%-os azonosságú vagy hasonlóságú szekvenciából áll.
10. Az 1., 2. és 6. igénypontok bármelyike szerinti Fab-ellenanyagfragmens, ahol a nehézlánc konstans régió SEQ ID NO:3 szerinti szekvenciával legalább 90%-os azonosságú vagy hasonlóságú szekvenciából áll.
11. A 10. igénypont szerinti Fab-ellenanyagfragmens, ahol a könnyűlánc konstans régió SEQ ID NO:4 szerinti szekvenciával legalább 90%-os azonosságú vagy hasonlóságú szekvenciából áll.
12. Az 1-11. igénypontok bármelyike szerinti Fab-ellenanyagfragmens, amelyhez egy vagy több effektormolekula hozzá van kapcsolva.
13. A 12. igénypont szerinti Fab-ellenanyagfragmens, amelyhez két vagy több effektormolekula van hozzá kapcsolva.
14. A 13. igénypont szerinti ellenanyagfragmens, ahol effektormolekula van kapcsolva egy könnyűlánc konstans régióban lévő ciszteinhez és egy nehézlánc konstans régióban lévő ciszteinhez.
15. A 14. igénypont szerinti ellenanyagfragmens, ahol a könnyűlánc konstans régióban és a nehézlánc konstans régióban lévő, effektormolekulákhoz kapcsolódó ciszteincsoportok egyébként, amennyiben az effektormolekulák nem kapcsolódnának hozzájuk, diszulfid hídon keresztül egymáshoz kapcsolódnának.
16. A 15. igénypont szerinti ellenanyagfragmens, ahol a könnyűláncban lévő cisztein, amelyhez effektormolekula van kapcsolva, a C_L -ben lévő láncközi cisztein, és a nehézláncban lévő cisztein, amelyhez effektormolekula van kapcsolva, a C_{H1} -ben lévő láncközi cisztein.
17. A 12-16. igénypontok bármelyike szerinti Fab-ellenanyagfragmens, ahol az effektormolekula PEG.
18. Eljárás a 12-17. igénypontok bármelyike szerinti Fab-ellenanyagfragmens előállítására, amely magában foglalja a következőket:
 - a. 1., 2., 3., 4., 5., 6., 7., 8., 9., 10. vagy 11. igénypont szerinti Fab-ellenanyagfragmens kezelése a nehézlánc és könnyűlánc konstans régióban lévő ciszteinben szabad tiolcsoportot képezni képes redukálószerrel,

b, a kezelt fragmens reagáltatása effektormolekulával.

19. A 18. igénypont szerinti eljárás, ahol a redukálószer nem tiol alapú redukálószer.

20. A 19. igénypont szerinti eljárás, ahol a redukálószer trialkilfoszfin.

21. A 20. igénypont szerinti eljárás, ahol a nem tiol alapú redukálószer trisz(2-karboxietil)-foszfin (TCEP).

22. A 20. igénypont szerinti eljárás, ahol a nem tiol alapú redukálószer trisz(3-karboxietil)-foszfin (THP).

23. A 18. igénypont szerinti eljárás, ahol az (a) vagy (b) lépések egyikét vagy mindegyikét kelátképzőszer jelenlétében végezzük.

24. A 23. igénypont szerinti eljárás, ahol a kelátképzőszer EDTA.

25. A 24. igénypont szerinti eljárás, ahol mind az (a), mind a (b) lépést EDTA jelenlétében végezzük.

26. Keverék, amely két vagy több Fab-ellenanyagfragmenst tartalmaz, azzal jellemezve, hogy a keverék dúsítva van olyan Fab-fragmensek tekintetében, amelyekben a C_{61} domén a láncközi ciszteinnél ér véget, és ahol a fragmensben a nehézlánc nincs kovalensen kötve a könnyűláncához, és a fragmensben a könnyűlánc és nehézlánc konstans régióban egy-egy ciszteinhez effektormolekula van kapcsolva.

27. A 26. igénypont szerinti keverék, ahol a keverék 50%-nál nagyobb része tartalmaz olyan Fab-fragmenst, amelyben a C_{61} domén a láncközi ciszteinnél ér véget, és ahol a fragmensben a nehézlánc nincs kovalensen kötve a könnyűláncához, és a fragmensben a könnyűlánc és nehézlánc konstans régióban egy-egy ciszteinhez effektormolekula van kapcsolva.

28. Izolált DNS-szekvencia, amely 3-11. igénypontok bármelyike szerinti Fab-ellenanyagfragmens nehéz- és/vagy könnyűlánc konstans régióját kódolja.

29. Klónozó vagy expressziós vektor, amely egy vagy több, 28. igénypont szerinti DNS-szekvenciát tartalmaz.

30. A 29. igénypont szerinti vektor, amely tartalmaz SEQ ID NO:5 szerinti szekvenciát.

31. A 30. igénypont szerinti vektor, amely tartalmazza a SEQ ID NO:6 szerinti szekvenciát is.

32. A 29. igénypont szerinti vektor, amely tartalmazza a SEQ ID NO:7 szerinti szekvenciát.

33. A 32. igénypont szerinti vektor, amely tartalmazza a SEQ ID NO:8 szerinti szekvenciát is.

34. Gazdasejt, amely 1., 2., 3., 4., 5., 6., 7., 8., 9., 10. vagy 11. igénypont szerinti Fab-ellenanyag-fragmenst expresszál.

35. A 34. igénypont szerinti gazdasejt, amely tartalmaz egy vagy több, 29-33. igénypontok bármelyike szerinti klónozó vagy expressziós vektort.

36. Eljárás 1., 2., 3., 4., 5., 6., 7., 8., 9., 10. vagy 11. igénypont szerinti Fab-ellenanyagfragmens előállítására, amely magában foglalja a 34. igénypont szerinti gazdasejt tenyésztését és a fragmens izolálását.

37. Gyógyászati készítmény, amely 1-17. és 26-27. igénypontok bármelyike szerinti Fab-ellenanyag-fragmenst tartalmaz, egy vagy több gyógyászati lag elfogadható segédanyaggal, hígítószerrel vagy hordozóval együtt.

A meghatalmazott:

DANUBIA

Szabadalmi és Irodai Kft.

Dr. Pethő Árpád
szabadalmi ügyvivő